Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mendel, Arielle | - |
dc.contributor.author | Bernatsky, Sasha | - |
dc.contributor.author | Pineau, Christian A. | - |
dc.contributor.author | St-Pierre, Yvan | - |
dc.contributor.author | Hanly, John G. | - |
dc.contributor.author | Urowitz, Murray B. | - |
dc.contributor.author | Clarke, Ann E. | - |
dc.contributor.author | Romero-Diaz, Juanita | - |
dc.contributor.author | Gordon, Caroline | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Wallace, Daniel J. | - |
dc.contributor.author | Merrill, Joan T. | - |
dc.contributor.author | Buyon, Jill | - |
dc.contributor.author | Isenberg, David A. | - |
dc.contributor.author | Rahman, Anisur | - |
dc.contributor.author | Ginzler, Ellen M. | - |
dc.contributor.author | Petri, Michelle | - |
dc.contributor.author | Dooley, Mary Anne | - |
dc.contributor.author | Fortin, Paul | - |
dc.contributor.author | Gladman, Dafna D. | - |
dc.contributor.author | Steinsson, Kristjan | - |
dc.contributor.author | Ramsey-Goldman, Rosalind | - |
dc.contributor.author | Khamashta, Munther A. | - |
dc.contributor.author | Aranow, Cynthia | - |
dc.contributor.author | Mackay, Meggan | - |
dc.contributor.author | Alarcon, Graciela | - |
dc.contributor.author | Manzi, Susan | - |
dc.contributor.author | Nived, Ola | - |
dc.contributor.author | Jonsen, Andreas | - |
dc.contributor.author | Zoma, Asad A. | - |
dc.contributor.author | van Vollenhoven, Ronald F. | - |
dc.contributor.author | Ramos-Casals, Manuel | - |
dc.contributor.author | Ruiz-Irastorza, Giuillermo | - |
dc.contributor.author | Lim, Sam | - |
dc.contributor.author | Kalunian, Kenneth C. | - |
dc.contributor.author | Inanc, Murat | - |
dc.contributor.author | Kamen, Diane L. | - |
dc.contributor.author | Peschken, Christine A. | - |
dc.contributor.author | Jacobsen, Soren | - |
dc.contributor.author | Askanase, Anca | - |
dc.contributor.author | Sanchez-Guerrero, Jorge | - |
dc.contributor.author | Bruce, Ian N. | - |
dc.contributor.author | Costedoat-Chalumeau, Nathalie | - |
dc.contributor.author | Vinet, Evelyne | - |
dc.date.accessioned | 2021-08-02T11:27:55Z | - |
dc.date.available | 2021-08-02T11:27:55Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/13347 | - |
dc.description.abstract | Objectives To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications. Methods This observational cohort study included premenopausal women ages 18–45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000–2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication. Results A total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)]. Conclusion CHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.identifier.doi | 10.1093/rheumatology/kez014 | - |
dc.identifier.scopusid | 2-s2.0-85068445914 | - |
dc.identifier.wosid | 000473771900022 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY, v.58, no.7, pp.1259 - 1267 | - |
dc.relation.isPartOf | RHEUMATOLOGY | - |
dc.citation.title | RHEUMATOLOGY | - |
dc.citation.volume | 58 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1259 | - |
dc.citation.endPage | 1267 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | COMBINED ORAL-CONTRACEPTIVES | - |
dc.subject.keywordPlus | VENOUS THROMBOSIS | - |
dc.subject.keywordPlus | ANTIPHOSPHOLIPID ANTIBODIES | - |
dc.subject.keywordPlus | NEUROPSYCHIATRIC EVENTS | - |
dc.subject.keywordPlus | PREGNANCY OUTCOMES | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | systemic lupus erythematosus | - |
dc.subject.keywordAuthor | anti-phospholipid syndrome | - |
dc.subject.keywordAuthor | contraception | - |
dc.subject.keywordAuthor | epidemiology | - |
dc.identifier.url | https://academic.oup.com/rheumatology/article/58/7/1259/5312899 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.